Skip to content

Surgical Resection Enhances Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Study

Surgical Resection Improves Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Propensity-Matched Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07026825
Acronym
SURGE
Enrollment
308
Registered
2025-06-18
Start date
2000-01-01
Completion date
2022-12-30
Last updated
2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric-type Endocervical Adenocarcinoma

Brief summary

This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Propensity score matching and multivariable Cox regression were used to compare overall survival (OS) and tumor-specific survival (TSS) between patients who underwent surgery and those who did not. The study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.

Detailed description

The study utilized de-identified data from the SEER program encompassing women aged ≥18 with histologically confirmed gastric-type endocervical adenocarcinoma between 2000 and 2021. The primary endpoints were overall survival and tumor-specific survival. Statistical analyses included multivariable Cox regression, propensity score matching (2:1), and inverse probability of treatment weighting (IPTW). Subgroup analyses were performed based on FIGO stage and tumor size (\>4 cm). A total of 308 eligible cases were included. No patient interaction or clinical intervention occurred.

Interventions

None listed

Sponsors

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Histologically confirmed gastric-type endocervical adenocarcinoma Cervix as the first primary site Diagnosis between 2000 and 2021

Exclusion criteria

Incomplete survival or treatment data Diagnosis not confirmed microscopically

Design outcomes

Primary

MeasureTime frameDescription
OutcomeTime from diagnosis to death from any cause Up to 22 years (2000-2022)Overall Survival (OS)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026